FDA-approved GHRH analog (Egrifta) for visceral fat reduction. Widely used off-label for body composition and IGF-1 optimization.
Pre-filled with standard Tesamorelin values. Adjust as needed.
Standard: 1–2mg subcutaneously once daily before bed on empty stomach. Check IGF-1 at 6 weeks to assess response. Standard protocol: 3–6 month cycles.
Blood markers to track
Note: FDA-approved as Egrifta. Strong IGF-1 response. Avoid if active malignancy. Monitor glucose.
Log IGF-1 (check at 6 weeks) and IGFBP-3 across draws and let StackAI analyze your response. Free to start.
Track my Tesamorelin labs free →